Getinge (GETI) investor relations material

Business transformation and operational improvements

• Significant progress in quality management and compliance, with most products now fully compliant and only two key 510(k)s pending approval.

• Sustained growth supported by strong customer loyalty and a shift to a more robust operational structure, resulting in improved margins.

• Company culture has evolved to focus on long-term goals and continuous improvement, enhancing customer service.

Regional market outlooks

• U.S. hospital capital expenditure demand remains robust, especially for operating room productivity and patient outcomes.

• EMEA continues to show strong momentum, particularly in Germany, with sustainable growth expected, though not at Q2's exceptional levels.

• China remains challenging due to macroeconomic factors, increased competition, and local content requirements, but growth is expected to align with the market at around 5% as conditions stabilize.

Segment performance and product innovation

• Life science order intake is strong, especially in the Americas, with bioprocessing and sterile transfer showing growth, though some pharma customers are delaying capital decisions due to geopolitical uncertainty.

• Acute care therapies rebounded from a sales decline to growth, driven by the Cardiohelp II launch and stable underlying demand linked to procedure volumes.

• Cardiohelp II offers improved technology and new application areas, with a full launch underway and a 510(k) submission for the ECMO system on track for the second half of 2026.